MiNK Therapeutics (MiNK Therapeutics) Total Assets : $6.89 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is MiNK Therapeutics Total Assets?

MiNK Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $6.89 Mil.

During the past 12 months, MiNK Therapeutics's average Total Assets Growth Rate was -36.50% per year. During the past 3 years, the average Total Assets Growth Rate was -14.00% per year.

During the past 5 years, MiNK Therapeutics's highest 3-Year average Total Assets Growth Rate was 22.00%. The lowest was -14.00%. And the median was 4.00%.

Total Assets is connected with ROA %. MiNK Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was -266.50%. Total Assets is also linked to Revenue through Asset Turnover. MiNK Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

MiNK Therapeutics Total Assets Historical Data

The historical data trend for MiNK Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiNK Therapeutics Total Assets Chart

MiNK Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

1.31

4.56

40.24

21.47

4.55

MiNK Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial												16.59	12.11	7.46	4.55	6.89

MiNK Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

MiNK Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-18.055	+	22.608
	=	4.55

MiNK Therapeutics's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	-20.299	+	27.193
	=	6.89

MiNK Therapeutics (NAS:INKT) Total Assets Explanation

Total Assets is connected with ROA %.

MiNK Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-15.252	/	( (4.552	+	6.894)	/ 2 )
	=	-15.252	/	5.723
	=	-266.50 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

MiNK Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (4.552	+	6.894)	/ 2 )
=	0	/	5.723
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

MiNK Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of MiNK Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

MiNK Therapeutics (MiNK Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

149 Fifth Avenue, Suite 500, New York, NY, USA, 10010

Website

https://www.minktherapeutics.com

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.

Executives

Agenus Inc	10 percent owner	3 FORBES ROAD, LEXINGTON MA 02421
Garo H Armen	director	3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg	director
Brian Corvese	director	C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Christine M Klaskin	officer: Treasurer	3 FORBES ROAD, LEXINGTON MA 02421
Jennifer Buell	director, officer: See Remarks	3 FORBES ROAD, LEXINGTON MA 02421
Barbara Ryan	director	22 CAVRAY ROAD, NORWALK CT 06855
Walter Md Flamenbaum	director	3 FORBES ROAD, LEXINGTON MA 02421
John Baldoni	director	3 FORBES ROAD, LEXINGTON MA 02421
Peter Behner	director	3 FORBES ROAD, LEXINGTON MA 02421
Van Dijk Marcus Antonius	officer: Chief Technology Officer	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010